Bysanti FDA Approval Status
FDA Approved: No
Brand name: Bysanti
Generic name: milsaperidone
Company: Vanda Pharmaceuticals Inc.
Treatment for: Bipolar Disorder, Schizophrenia
Bysanti (milsaperidone) is an atypical antipsychotic in development for the treatments of acute bipolar I disorder and schizophrenia.
Development timeline for Bysanti
| Date | Article |
|---|---|
| Mar 31, 2025 | Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti for the Treatments of Acute Bipolar I Disorder and Schizophrenia |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.